Hydroxyurea Dosing for Essential Thrombocythemia
For essential thrombocythemia requiring cytoreduction, start hydroxyurea at 15 mg/kg once daily (or 7.5 mg/kg if creatinine clearance <60 mL/min), with a target platelet count <400 × 10⁹/L. 1
Initial Dosing Strategy
The FDA-approved starting dose is 15 mg/kg once daily based on actual or ideal body weight (whichever is less) 1. This translates to approximately 1000-1500 mg daily for most adults, though the evidence from clinical practice suggests weekly doses averaging 7500 mg (approximately 1000-1100 mg daily) 2.
Key dosing adjustments:
- Renal impairment (CrCl <60 mL/min or ESRD): Reduce initial dose by 50% to 7.5 mg/kg once daily 1
- Body weight >80 kg: May require up to 2.5 g/day to achieve response 3
- On dialysis: Administer after hemodialysis 1
Treatment Target and Response Assessment
The optimal treatment target is platelets <400 × 10⁹/L 3. This is the validated endpoint for daily practice, though complete hematological response (CHR) provides the best outcomes in high-risk patients 4.
Monitor blood counts at least weekly during therapy 1. Assess response at 3 months - this is the critical timepoint for determining resistance or need for dose adjustment 3.
Defining Treatment Failure
Resistance/intolerance to hydroxyurea is defined as: 3
- Platelet count >600 × 10⁹/L after 3 months of at least 2 g/day (2.5 g/day if weight >80 kg), OR
- Platelet count >400 × 10⁹/L with WBC <2500/μL at any dose, OR
- Platelet count >400 × 10⁹/L with Hb <10 g/dL at any dose, OR
- Leg ulcers or unacceptable mucocutaneous manifestations at any dose, OR
- Hydroxyurea-related fever
Clinical Context and Pitfalls
Common pitfall: Underdosing due to fear of myelosuppression. The evidence shows that achieving CHR (which often requires adequate dosing up to 2-2.5 g/day) significantly reduces arterial thrombosis risk (HR 0.35) in high-risk patients 4. Conversely, suboptimal dosing that fails to achieve platelet control leaves patients at continued thrombotic risk.
Important consideration: Hydroxyurea remains the first-line cytoreductive agent for high-risk ET based on guideline recommendations 5, 3. The 2018 European LeukemiaNet guidelines specifically endorse hydroxyurea as first-line therapy, with pegylated interferon-α and anagrelide as alternatives for specific situations 5.
Prophylactic folic acid is recommended during hydroxyurea therapy 1, though the specific dose is not defined in the FDA label.
Alternative Dosing Strategies
Emerging evidence suggests intermittent hydroxyurea (20 mg/kg three times weekly) may be effective in select patients, including those deemed resistant or intolerant to continuous therapy 6. However, this remains investigational and should not replace standard daily dosing as initial therapy.
Monitoring Requirements
- Weekly CBC during therapy 1
- Dose reduction or discontinuation for:
- Myelosuppression (specific thresholds not defined but monitor neutrophils and platelets)
- Cutaneous vasculitis
- Other significant toxicities 1
Critical safety note: Hydroxyurea is teratogenic - verify pregnancy status before starting and ensure effective contraception (6 months post-therapy for females, 1 year for males) 1.